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Background. The aim of our study was to evaluate the serum concentration of klotho in a cohort of systemic sclerosis (SSc)
patients compared to that of healthy controls and to correlate its levels with the degree and the kind of organ involvement.
Methods. Blood samples obtained from both patients and controls were collected and analysed by an ELISA test for the
determination of human soluble klotho. Scleroderma patients were evaluated for disease activity through clinical,
laboratory, and instrumental assessment. Results. Our cohort consisted of 81 SSc patients (74 females, mean age 63.9± 13.1 years)
and 136 healthy controls (78 females, mean age 50.5± 10.7 years). When matched for age, serum klotho concentration
signiﬁcantly diﬀered between controls and patients (p < 0 001). However, in SSc patients, we did not ﬁnd any signiﬁcant
association between serum klotho and clinical, laboratory, and instrumental ﬁndings. Lower serum levels of klotho were
detected in 4 patients who were anticitrullinated peptide antibody (ACPA) positive (p = 0 005). Conclusions. Our data show
a lower concentration of klotho in the serum of SSc patients compared to that of healthy controls, without any signiﬁcant
association with clinical manifestations and laboratory and instrumental ﬁndings. The association between serum klotho
and ACPA positivity requires further investigation.
1. Introduction
Systemic sclerosis (SSc) is a connective tissue disease char-
acterized by microangiopathy, activation of the immune
system, and ﬁbrosis. Raynaud’s phenomenon, skin sclero-
sis, digital ulcers, subcutaneous calcinosis, lung interstitial
disease, esophageal dysmotility, and renal crisis represent
some of the most peculiar features of the disease. Endo-
thelial dysfunction may represent the primum movens in
the pathogenesis of SSc. Consecutive episodes of vaso-
constriction and riperfusion contribute to the generation
of oxidative stress, to the activation of the immune
response, and to the induction of reparative processes,
leading to ﬁbrosis.
Klotho is a transmembrane and soluble protein that
displays a glucosidase activity, although it mainly acts as a
coreceptor. Klotho is involved in mineralization, electrolytic
balance, insulin sensitivity, cell renewing, and reparative pro-
cesses. Transgenic mice lacking klotho expression develop a
phenotype characterized by accelerated aging, skin atrophy,
lung emphysema, osteoporosis, delayed wound healing, and
vascular calciﬁcation.
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A deﬁciency in klotho expression could be responsible for
microangiopathy, calcinosis, and ﬁbrosis, which represent
hallmarks of SSc.
We wondered, therefore, if serum concentration of
klotho could be reduced in patients suﬀering from SSc, being
also related to the severity of the disease or speciﬁc clinical
manifestations.
The aim of our study was to evaluate the serum con-
centration of klotho in a group of SSc patients compared
to healthy controls and to correlate its levels with the
degree and the kind of organ involvement, assessed
through Medsger’s scale score and laboratory, instrumental,
and functional tests.
2. Methods
We enrolled 81 consecutive Caucasian patients aﬀected by
SSc, according to 2013 ACR/EULAR criteria [1] and 136
matched healthy controls. Enrolment time took place since
October 2014 until April 2016.
Blood samples obtained from both patients and controls
were collected and analysed through an enzyme-linked
immunosorbent assay (ELISA) assay for the determination
of human soluble klotho by using a monoclonal anti-KL anti-
body and a KL-HRP conjugate (My Biosource, CA, USA).
The sensitivity in this assay was 0.1 ng/mL. Blood samples
were centrifuged, and sera were stored for a maximum of
six months at −80°C until utilization.
Disease severity was scored through Medsger’s scale
[2]. In addition, modiﬁed Rodnan skin score (mRSS) for
the degree and the extension of cutaneous sclerosis; pul-
monary function tests for the assessment of forced vital
capacity (FVC) and diﬀusing capacity or transfer factor
of the lung for carbon monoxide per unit alveolar volume
(DLCO/AV); chest high-resolution computed tomography
(HRCT) scan for the detection of lung ﬁbrosis; 2D echo-
cardiography (2D-ECHO) for the screening of pulmonary
artery hypertension (PAH); and laboratory tests for the
determination of serum creatinine level, autoantibodies,
erythrocyte sedimentation rate (ESR), and C-reactive protein
(CRP) were also performed. Right heart catheterization was
performed in a minority of patients but was not included
in our analysis.
Subjects suﬀering from uncontrolled diabetes, lung
obstructive disease, or renal failure unrelated to systemic
sclerosis were excluded. Furthermore, patients with overlap-
ping connective tissue diseases that could compromise the
renal function, such as systemic lupus erythematosus (SLE),
were also excluded from the analysis.
Data were reported as mean± standard deviation (SD)
or median, range, and interquartile range (IQR) as appro-
priate. Wilcoxon’s test for unpaired samples was used for
the comparison of klotho serum concentration between
patients and healthy controls. In the group of sclero-
derma patients, Spearman’s rank correlation coeﬃcient
was used to compare the level of klotho with clinical, labora-
tory, and instrumental ﬁndings. p value was set at <0.05.
Statistical analysis was performed using a SPSS calculator,
version 23.
The protocol was approved by our local ethic com-
mittee and registered with the number 88 of 05 February
2015 and conducted according to the Declaration of Hel-
sinki. Patients and healthy subjects were informed about
the procedures of the study and signed an informed
consent.
3. Results
Our cohort consisted of 81 SSc patients (74 females, mean
age 63.9± 13.1 years, mean disease duration 12.4± 8.9 years)
and 136 healthy controls (78 females, mean age 50.5± 10.7
years). In the group of SSc patients, 22 (27.1%) suﬀered from
diﬀuse form of disease and 59 (72.8%) from limited form.
Median mRSS was 4.5 (range 0–30; IQR 6.8) and mean
Medsger’s scale score was 4.3± 2.3. Antinuclear antibodies
(ANAs) were detected in 74 SSc patients (91.3%); among
whom, 41 (50.6%) were positive for anticentromere and
19 (23.4%) for anti-SCL70 autoantibodies. Antiextractable
nuclear antigen autoantibodies (ENA) anti-LaSSB and
anti-RoSSA were present, respectively, in 2 and 10 patients;
anticitrullinated peptide antibodies (ACPA) in 4 patients;
rheumatoid factor (RF) in 1 patient; antimitochondrial
antibodies (AMA) in 2 patients; antiphospholipid anti-
bodies IgM and IgG in 6 patients; and anti-Jo1 and anti-
ribonucleoprotein (RNP) autoantibodies, respectively, in 1
and 1 patient.
Chest HRCT showed pulmonary ﬁbrosis in 35 (43.2%)
patients; and 2D-ECHO detected the signs of PAH in 19
(23.4%) patients. Digital ulcers were objectiﬁed in 18
(22.2%) cases and calcinosis in 14 (17.3%) cases. Overall, lab-
oratory tests showed normal to mild increased ESR values
(median 15 mm 1st hour, range 2.0–84, IQR 22.8; normal
range 0–20mm), with a CRP within the range of normality
(median 2.1mg/L, range 0–24, IQR 3.6; normal range
0–10mg/L). Renal function was globally preserved (median
serum creatinine 0.7mg/dL, range 0.49–2.22, IQR 0.3). Four
patients showed an increase in serum creatinine value over
the upper limit of the normal range without any further sign
of kidney failure.
Table 1 shows the clinical and demographic characteris-
tics of the SSc cohort.
Patients were treated with calcium channels blockers
(27 cases), i.v. prostanoids (all), and immunosuppressive
drugs (prednisone 2–12.5mg/day in 26 cases; hydroxychlor-
oquine 200–400mg/day in 17 cases; mycophenolate mofetil
1-2 g/day in 3 cases; methotrexate 10–20mg/week in 7 cases;
cyclosporin A 100mg/day in 1 case; and azathioprine
100–200mg/day in 5 cases). Moreover, 23 patients assumed
acetylsalicylic acid, 10 patients bosentan, and 14 patients
angiotensin-converting enzyme inhibitors.
In healthy controls, serum klotho concentration ranged
from 0.0 to 1.70 ng/mL (median 0.61 ng/mL, IQR 0.60). In
SSc patients, serum klotho concentration ranged from 0.0
to 2.50 ng/mL (median 0.30ng/mL, IQR 0.79). These values
are in line with previous results obtained from healthy pop-
ulation by means of ELISA assays [3, 4]. Serum klotho was
not associated to sex or age in the group of scleroderma
patients. On the contrary, in the control group, serum
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klotho was directly related to age (ρ 0.304, F 14.6,
p < 0 001), despite that no association with sex was found.
When the two groups were matched for age, serum klotho
levels were signiﬁcantly reduced in patients compared to
controls (p < 0 001) (Figure 1).
Spearman’s test did not ﬁnd any signiﬁcant correla-
tion between klotho and each of the clinical, laboratory,
and instrumental variables. When patients were subdi-
vided according to the presence of calcinosis, digital
ulcers, lung ﬁbrosis, echocardiographic signs of PAH,
or disease subtype, no signiﬁcant diﬀerence was observed
in serum klotho concentration using a nonparametric
test for unpaired samples (Wilcoxon’s test). However,
when evaluated for the presence of a speciﬁc pattern
of autoantibodies, patients being ACPA positive showed
signiﬁcantly lower levels of serum klotho (median values
0.10 ng/mL versus 0.30 ng/mL; U 25.500, Z −2.802,
p = 0 005) than those who were not (Figure 2). Serum klotho
Table 1: Demographic and clinical characteristics of SSc patients.
Characteristics Scleroderma patients (number 81)
Age (years) (mean± standard deviation) 63.9± 13.1
Sex (F/M) (number) 74/7
Disease duration (years) (mean± standard deviation) 12.4± 8.9
Clinical form (limited/diﬀuse) (number) 59/22
Antinucleus autoantibody positivity (number) 74
Anticentromere autoantibody positivity (number) 41
Anti-SCL70 autoantibody positivity (number) 19
Erythrocyte sedimentation ratio, 1st hour mm (median, range) 15, 2.0–84
C-reactive protein, mg/L (median, range) 2.1, 0–24
Serum creatinine, mg/dL (median, range) 0.7, 0.49–2.22
Digital ulcers (number) 18
Calcinosis (number) 14
Pulmonary artery hypertension screened through 2D echocardiography (number) 19
Lung interstitial disease (number) 35
Diﬀusing capacity or transfer factor of the lung for carbon monoxide per unit alveolar volume (%)
(mean± standard deviation) 83.3± 15.2
Vital capacity (%) (mean± standard deviation) 100.3± 17.4
Medsger’s scale score (mean± standard deviation) 4.3± 2.3
Modiﬁed Rodnan skin score (median, range) 4.5, 0–30
Osteoporosis (number) 32
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Figure 1: Serum klotho concentrations in matched scleroderma
patients and healthy controls with reported median values.
SSC= systemic sclerosis; HC=healthy controls.
2.50
2.00
Se
ru
m
 k
lo
th
o 
(n
g/
m
L)
0.30 ng/mL
Negative Positive
ACPAs
0.10 ng/mL
p =
1.50
1.00
0.50
0.00
0.005
Figure 2: Serum klotho concentration with reported median values
according to anticitrullinated peptide antibody (ACPA) positivity in
scleroderma patients.
3Disease Markers
levels were not signiﬁcantly inﬂuenced by concomitant
treatments.
4. Discussion
Firstly described in 1997 by Kuro-o and colleagues as an
aging-contrasting factor [5], klotho is a single-pass trans-
membrane protein, mainly expressed in the distal convolute
tubules of the kidney and generated in 2 isoforms: α- and
β-klotho. Klotho may act as a glucosidase or coreceptor by
means of a paracrine or endocrine way [6]. Trasmembrane
klotho cleaved by metalloproteinases in a soluble form main-
tains its functions [7]. This marker has gained interest over
the time in the pathogenesis of kidney failure, where a lack
of the protein seems to be associated to a declined estimated
glomerular ﬁltration rate [8–10]. More recently, klotho has
been considered an antagonist for the proliferation of malig-
nant cells, through ﬁbroblast growth factor receptor (FGFR)
and Wnt/β-catenin signalling pathways [11].
Soluble klotho may antagonize Wnt and transforming
growth factor-β (TGF-β) signaling thus preventing tissue
ﬁbrosis and cancer metastasis [12–14].
It has been reported that klotho may increase the
abundance on plasma membranes of transient receptor
potential vanilloid receptor-related channels (TRPV5); it
may interact with the Na+/K+ ATPase and insulin recep-
tors and strengthen the aﬃnity between ﬁbroblast growth
factors 19, 21, and 23 (FGF19, FGF21, and FGF23) and
their receptors [15–17].
In particular, by interacting with FGF23 receptor, α-
klotho may reduce the expression of α1-hydroxylase in the
kidney, thus lowering the concentration of 1,25(OH)2D3
and preventing the reabsorption of calcium and phosphate
from the kidney proximal tubules. Klotho mutant mice
develop early hyperphosphatemia and hypercalcemia with
a high risk of ectopic calciﬁcations and accelerated osteopo-
rosis due to a reduction in the number of both osteoclasts
and osteoblasts.
Klotho is involved in the regulation of intracellular Ca2+
entry, whose amount presides over many biological activities,
including vessel tone control and wound healing [18]. Cal-
cium homeostasis is crucial for the correct functioning of
endothelial cells. The amount of intracellular calcium, mainly
released from endoplasmic reticulum, regulates many biolog-
ical activities, including proliferation and apoptosis. TRP
receptors modulate the entrance of calcium into endothelial
cells in a klotho-dependent manner. In murine models,
klotho seems in fact to prevent the junction disruption and
the apoptosis of endothelial cells, by binding to the complex
vascular endothelial growth factor receptor (VEGFR)/
TRPC-1 and indirectly regulating the intracellular calcium
concentration [19]. Endothelial cells from klotho mutant
mice show a deﬁcit in the internalization of TRPC-1 with
an augmented calcium inﬂux and a consequent increased
activity of calcium-dependent proteases cleaving adhesion
molecules. Moreover, a deﬁcit in klotho expression is related
to a reduced production of endothelial nitric oxide (NO),
with a repercussion on vascular tone and apoptosis of
vascular smooth muscle cells (VSMC).
Some authors have also demonstrated that klotho
may inhibit the secretion of several cytokines, such as
interleukin-6 and interleukin-8 (IL-6 and IL-8), by bind-
ing retinoic acid-inducible gene-I (RIG-1) [20]. Mice
lacking klotho expression experiment an impairment in
B-lymphopoiesis which is not rescued by the addiction of
IL-7, while myeloid and erythroid cells are not aﬀected [21].
Conversely, other studies have shown that other
inﬂammatory cytokines, including tumor necrosis factor-α
(TNF-α), may reduce klotho expression through NF-kB [22].
Systemic sclerosis is a connective tissue disease character-
ized by Raynaud’s phenomenon and a progressive cutaneous
ﬁbrosis extending from distal to proximal sites. In the most
severe forms, ﬁbrosis aﬀects also internal organs, determining
various clinical pictures ranging from interstitial lung disease
to restrictive heart disease or dysphagia, heavily inﬂuencing
the prognosis. Although the disease is characterized by the
detection of speciﬁc autoantibodies (mostly anticentromere
and anti-SCL70), the pathogenic role of the immune system
is probably less important than in other autoimmune connec-
tive tissue diseases. On the contrary, the endothelial dysfunc-
tion and the aberrant activation of ﬁbroblasts play a more
crucial role in the induction and maintenance of SSc. Several
soluble vascular markers, including soluble intercellular
adhesion molecule- (sICAM-) 1, vascular endothelial growth
factor (VEGF), and endostatin, are altered in SSc and may
vary according to the course of the disease [23, 24]. In addi-
tion, the research on animal models has demonstrated the
involvement of endothelial cells, pericytes, and myoﬁbro-
blasts in the pathogenesis of SSc, culminating in an impaired
process of tissue healing and reparation [25].
Klotho participates to many biologic activities related to
vascularization, collagen production, calciﬁcation, and tissue
repair and may therefore be involved in the pathogenesis of
SSc in several ways (Figure 3).
By interacting with VEGFR and TRP and regulating
intracellular calcium balance, klotho may counteract the
phenomenon of ectopic calciﬁcation, contribute to endothe-
lial stability, and prevent oxidative stress [26]. Furthermore,
klotho may inhibit the collagen deposition by antagonizing
TGF-β. The secretion of some cytokines such as IL-6,
which is fundamental for the maturation of plasma cells
and the production of autoantibodies, may be increased in
case of deﬁcit of klotho. As demonstrated in several exper-
iments on murine asthma models and human bronchial
epithelial cells, klotho may counteract the remodeling of
airways and prevent lung ﬁbrosis by interfering with
TGF-β1 and VEGF [27].
Klotho mutant mice display a phenotype characterized
by accelerated aging, atherosclerosis, osteoporosis, and
lung obstructive disease [5]. Moreover, mice lacking klotho
expression have also a delay in skin wound healing, partly
due to a deﬁcit of type 1 and type 3 collagen depositions
[18]. Similarly, SSc is currently considered as an acceler-
ated aging phenotype, partly relying on altered epigenetic
control [28, 29].
Our results show a signiﬁcant diﬀerence in the serum
concentration of klotho of SSc patients and healthy con-
trols; however, the level of klotho was not associated to
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disease severity, according to Medsger’s scale, and to clin-
ical, laboratory, and instrumental ﬁndings, neither to a
particular manifestation of the disease. In line with our
data, a recent experiment investigating the association
between klotho and precapillary PAH did not achieve
any conclusive result [30]. We found a signiﬁcant associa-
tion between low klotho levels and the positivity for
ACPAs. ACPAs represent a hallmark for rheumatoid
arthritis (RA), and SSc patients having detectable ACPA
titres often suﬀered from arthralgias or arthritis. A group of
researchers demonstrated a reduced expression of klotho in
CD4+ lymphocytes from RA patients [31]; however, it is
unclear whether the reduced klotho expression could mirror
an accelerating aging process of the cells belonging to the
immune system.
The use of soluble klotho as a biomarker has been inves-
tigated in systemic lupus erythematosus (SLE) [32], and
more recently, its proangiogenic eﬀect has been tested in a
wound healing assay using human SSc-derived microvascu-
lar endothelial cells [33].
Our pivotal study has some limits. Firstly, we did not
analyse separately the serum concentration of alpha- and
beta-klotho that may account for some diﬀerences in biolog-
ical activities. Secondly, evidences showed that ELISA kits for
klotho detection have low sensitivity, perhaps attributable to
the recognition of diﬀerent isoforms of the protein [3]. More-
over, our study evaluated the soluble fraction of klotho,
exploring its hormonal functions; but we did not perform
immunohistochemical tests on SSc tissues, so the real
amount of klotho, either as soluble or transmembrane, pro-
duced in situ and presiding a paracrine control, was not
assessed. Thirdly, the serum concentration of FGF23 was
not measured, as well as of other endothelial or ﬁbroblastic
markers. Finally, we did not evaluate the presence of a
receptorial resistance to klotho or the presence of dysfunc-
tional isoforms of the molecule (e.g., polymorphic variants).
5. Conclusions
Klotho is a novel biomarker involved in aging, cancer, and
multiorgan dysfunction. Among its biological activities,
klotho preserves the integrity of microvessels and favors the
process of healing and tissue reparation. A deﬁcit in klotho
concentration may explain some of the clinical manifestation
observed in SSc, such as digital ulcers, calcinosis, or ﬁbrosis.
Our data show a signiﬁcant diﬀerence in the concentration
of serum klotho between SSc patients and controls with an
overall serum concentration being in line with that of general
population. Nevertheless, we did not ﬁnd any signiﬁcant
association among the serum levels of klotho and clinical
manifestations of the disease or the severity of SSc expres-
sion. We found a signiﬁcant association between low serum
klotho concentration and the presence of ACPAs, but the sig-
niﬁcance of this ﬁnding is unclear. In conclusion, as this was
a pivotal study and some limits can occur, further studies in
order to understand the real involvement of klotho in the
pathogenesis of SSc are suggested.
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